Guardant Health, Inc. officer Terilyn J. Monroe submitted a Form 144 notice of proposed sale on November 18, 2026, disclosing plans to sell 3,842 shares of common stock through Charles Schwab & Co., Inc.

Key Highlights

  • Proposed sale: 3,842 shares of Guardant Health common stock with an aggregate market value of $547,149.00
  • Seller: Terilyn J. Monroe, identified as an officer of Guardant Health, Inc.
  • Shares outstanding: 135,285,975 shares of common stock outstanding at the time of filing
  • Acquisition source: Two restricted stock lapses of 1,921 shares each, acquired July 1, 2026 and October 1, 2026, both from Guardant Health as equity compensation
  • 10b5-1 plan: The notice indicates a Rule 10b5-1 plan adoption date of August 19, 2026
  • Approximate sale date: November 18, 2026, to be executed through Charles Schwab & Co., Inc. on NASDAQ
  • Prior three-month sales: Nothing to report

Monroe's Proposed Share Sale Under Rule 144 at Guardant Health

According to the filing, Terilyn J. Monroe, an officer of Guardant Health, Inc. (NASDAQ:GH), filed a Form 144 notice on November 18, 2026, disclosing a proposed sale of 3,842 shares of the company's common stock. The aggregate market value of the shares to be sold is listed as $547,149.00. The filing identifies Charles Schwab & Co., Inc., located at 3000 Schwab Way, Westlake, TX 76262, as the named broker for the transaction.

The filing discloses that the shares to be sold were acquired through two separate restricted stock lapse transactions, each involving 1,921 shares. The first lapse occurred on July 1, 2026, and the second on October 1, 2026, with both acquisitions attributed to Guardant Health, Inc. as equity compensation. The filing classifies the nature of payment for both acquisitions as equity compensation.

The notice states that Monroe is relying on a Rule 10b5-1 plan, with an adoption date of August 19, 2026. The filing further discloses that Monroe reports no sales of Guardant Health securities during the three months prior to this notice. At the time of the filing, the company had 135,285,975 shares of common stock outstanding, according to the disclosure.

What Was Disclosed

The Form 144 filing by Guardant Health officer Terilyn J. Monroe covers a proposed sale of 3,842 shares valued at $547,149.00, acquired via restricted stock lapses in July and October 2026, to be executed under a Rule 10b5-1 plan adopted August 19, 2026.